Vimarsana
Biggest News Aggregation in the World

Page 14 - Drug Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Programs Today - Breaking & Trending Today

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting - Vimarsana News

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting

Published: November 3, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongAscentage PharmaDajun YangYifan ZhaiMajor NationalTanner Pharma GroupMd Anderson Cancer CenterAmerican Society Of HematologyNational Major New Drug DiscoveryChina National Medical Products AdministrationDana Farber Cancer InstituteChina Ministry Of ScienceCancer AssociationDrug AdministrationGlobal Named Patient ProgramEuropean Medicines AgencyPatient ProgramAmerican SocietyNew OrleansMajor New Drug ProjectChinese SocietyClinical OncologyChina Anti Cancer AssociationHolistic Integrative Management
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting - Vimarsana News

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Published: October 20, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongWestern AustraliaAscentage PharmaYifan ZhaiJinlin HouPrnewswire Ascentage PharmaMajor NationalMd Anderson Cancer CenterWaltere Washington Convention CenterNational Major New Drug DiscoveryInstitute Of HepatologyChina National Medical Products AdministrationSouthern Medical University Affiliated Nanfang HospitalDana Farber Cancer InstituteAmerican AssociationLiver Diseases Annual MeetingLiver DiseasesChief Medical OfficerFirst In Human StudyTargeting InhibitorApoptosis ProteinsChronic HepatitisNovel Therapeutic Approaches AimedFunctional Cure
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting - Vimarsana News

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Published: October 19, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongWestern AustraliaAscentage PharmaYifan ZhaiJinlin HouPrnewswire Ascentage PharmaMajor NationalMd Anderson Cancer CenterWaltere Washington Convention CenterNational Major New Drug DiscoveryInstitute Of HepatologyChina National Medical Products AdministrationSouthern Medical University Affiliated Nanfang HospitalDana Farber Cancer InstituteAmerican AssociationLiver Diseases Annual MeetingLiver DiseasesChief Medical OfficerFirst In Human StudyTargeting InhibitorApoptosis ProteinsChronic HepatitisNovel Therapeutic Approaches AimedFunctional Cure
Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential - Vimarsana News

Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential

Published: September 21, 2022

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com
Related Topics:
United StatesHong KongQian JiangWestern AustraliaAscentage PharmaTanner PharmaYifan ZhaiXiaojun HuangMajor NationalInstitute Of HematologyMd Anderson Cancer CenterAmerican Society Of HematologyChina National Medical Products AdministrationNational Major New Drug DiscoveryDana Farber Cancer InstituteHematology Department At Peking University People HospitalChinese Society Of Clinical OncologyCancer AssociationNational Major New Drug DevelopmentGlobal Named Patients ProgramDrug AdministrationOncologist NetworkEuropean Medicines AgencyManufacturing ProgramImpact Factor
Ascentage Pharma Announces 2022 Interim Results - Vimarsana News

Ascentage Pharma Announces 2022 Interim Results

Published: August 27, 2022

SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis

Source: finanznachrichten.de
Related Topics:
United StatesHong KongInnovent BiologicsAscentage PharmaDajun YangTanner PharmaPrnewswire Ascentage PharmaMajor NationalAmerican Society Of Clinical OncologyEuropean Hematology AssociationEuropean Molecular Biology OrganizationMd Anderson Cancer CenterChina National Medical Products AdministrationNational Major New Drug DiscoveryDana Farber Cancer InstituteChinese Society Of Clinical OncologyCancer AssociationNational Major New Drug DevelopmentDrug AdministrationHealth CanadaManufacturing ProgramPatient ProgramChinese SocietyClinical OncologyChina Anti Cancer Association